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Edited by Lukas HuberAbstract To investigate the eﬀect of Epstein-Barr virus (EBV)
latent membrane protein 1 (LMP1) on human cancer cells, we
sought to identify and analyze potential target genes that were
diﬀerentially expressed in the presence and absence of LMP1.
Our cDNA microarray analysis revealed that expression of early
growth response gene-1 (Egr-1) was increased by LMP1 expres-
sion in MCF7 and Jurkat cells. An NFjB inhibitor (SN50)
antagonized LMP1-induced enhancement of Egr-1 expression,
indicating that LMP1 induced Egr-1 via NFjB. Furthermore,
three lines of evidence indicated that Egr-1 was required for
LMP1-induced cancer cell survival. First, Egr-1 expression en-
hanced the survival of doxorubicin-treated MCF7 cells. Second,
inhibition of Egr-1 expression by siRNA (siEgr-1) eﬀectively
suppressed LMP-1-induced survival of MCF7 cells. Third,
Egr-1 knockdown decreased LMP1-induced expression of Bﬂ-
1. Similar relationships among EBV infection, Egr-1 and drug
resistance were also observed in tissues of peripheral T-cell lym-
phoma-unspeciﬁed (PTCL-u) patients.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Epstein-Barr virus (EBV) is a potentially oncogenic human
herpesvirus capable of infecting lymphoid and epithelial cells.
EBV infection has been associated with multiple diseases,
including Burkitt’s lymphoma, Hodgkin’s disease, lymphopro-
liferative disorders, certain types of T-cell lymphoma, and
nasopharyngeal carcinoma (NPC) and breast cancer [1–6].
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doi:10.1016/j.febslet.2007.01.020membrane protein that has been shown to be essential for
EBV-induced immortalization of B cells [7]. LMP-1 has onco-
genic properties associated with stimulation of DNA synthesis,
transcriptional activation of anti-apoptotic genes (e.g. NFjB),
and suppression of cellular senescence [8–12]. However,
although the connection between LMP1 and cancer has been
relatively well established, its molecular targets have not been
fully established.
The early growth response (Egr) gene family consists of
Egr-1, Egr-2, Egr-3, and Egr-4 [13], all of which share high
homology in DNA-binding domains. Deﬁciency of Egr-1
signiﬁcantly reduced cancer progression [14], and the identiﬁed
targets of Egr-1 include PDGF-A, IGF-II, and cyclinD, which
are known as stimulators of cancer [15].
In the present study, we sought to identify molecular targets
of LMP1 and examined the eﬀects of a speciﬁc LMP1 target on
the chemo-susceptibility of EBV-infected cancer cells. Micro-
array analysis revealed that LMP1 induced Egr-1 expression
in human cancer cells. Additional analyses revealed that Egr-
1 knockdown diminished LMP1-induced cell survival, and
treatment with an NFjB inhibitor abrogated LMP1-induced
Egr-1 expression, suggesting the involvement of NFjB in this
response. Associations among Egr-1 expression, drug resis-
tance and the presence of EBV were also observed in tissue
samples from peripheral T-cell lymphoma patients.2. Materials and methods
2.1. Cell lines, culture conditions and transfection
MCF7 and Jurkat cell lines were purchased from the American Type
Culture Collection (Rockville, MD), and cultured in RPMI 1640 sup-
plemented with heat-inactivated 10% fetal bovine serum, penicillin,
and streptomycin (Gibco-BRL,Grand Island, NY) in 5% CO2. The
human NKTL cell lines, EBV-negative NKL and EBV-positive
HANK1 [16], were kindly provided by Dr. M. Seto (Aichi Cancer Cen-
ter Hospital, Nagoya, Japan). The LMP1 expression plasmids, includ-
ing pcDNA3.1-LMP1 and an NFjB activation-deﬁcient LMP1
mutant (LMP1DNFjB) [17], were obtained from Dr. Y.H. Ko (Sam-
sung Medical Center, Seoul, Korea) and Dr. Y. Cao (Central South
University, Changsha, China), respectively. The Egr-1 expression con-
structs, pEgr-1 and pEgr-1* (constitutively active Egr-1) [18] were
kindly provided by Dr. D.-K. Kim (Samsung Medical Center, Seoul,
Korea). MCF7 and Jurkat cells were transiently transfected with theseblished by Elsevier B.V. All rights reserved.
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burg, MD), which produced transfection eﬃciencies of >80% in both
cell types, as assessed by microscopic observation.
2.2. cDNA microarray analysis
A cDNA microarray containing 17448 sequence-veriﬁed human
cDNA clones was purchased from GenomicTree Inc. (Seoul, Korea).
The target cDNA probes were synthesized and hybridizations were
performed as previously described [19]. After hybridization, the micro-
arrays were washed and immediately dried in a microarray centrifuge
(GenomicTree Inc.). All microarray hybridizations were performed in
duplicate, and the collected data were averaged.
2.3. Data acquisition and analysis
The hybridization images were analyzed using a GenePix Pro 4.0
(Axon Instruments, CA). The average ﬂuorescence intensity for each
spot was calculated, and the local background was subtracted. All data
normalization and statistical analysis were performed using the Gene-
Spring 6.1 (Silicon Genetics, USA). Genes were ﬁltered according to
the two-component model for estimating variation from control
strength. Intensity-dependent normalization was performed, where
the ratio was reduced to the residual of the Lowess ﬁt of the intensity
versus ratio curve. The averages of normalized ratios were calculated
by dividing the average of normalized signal channel intensity by the
average normalized control channel intensity. Hierarchical clustering
was performed by similarity measurements based on Pearson correla-
tions around 0. Functional annotation of genes was performed accord-
ing to information available at the Gene Ontology Consortium website
(http://www.geneontology.org/index.shtml) using the GeneSpring 6.1
software package.2.4. RT-PCR analysis
Total RNA was prepared using TRIZOL reagent (Invitrogen, San
Diego, CA) according to the manufacturer’s instructions. For re-
verse-transcription (RT), 2 lg of RNA was treated with RNase-free
DNase, and cDNA was obtained using Moloney murine leukemia
virus reverse transcriptase. The generated cDNA was PCR ampliﬁed
using primers speciﬁc for LMP1 (5 0-GTG ACT GGA CTG GAG
GAG CC-3 0 and 5 0-AGG GAG TCA TCG TGG TGG TG-3 0) or
Egr-1 (5 0-CTA AGC TGG AGG AGA TGA TG-3 0 and 5 0-ACC
TTC TCG TTG TTC AGA GA-3 0), and 25 cycles (LMP1) or 35 cycles
(Egr-1) of 30 s at 95 C, 30 s at 58 C, and 30 s at 72 C. Actin was
ampliﬁed as a control. The PCR products were visualized by 2% aga-
rose gel electrophoresis in 1· TBE buﬀer containing 0.5 lg/ml ethidium
bromide.Table 1
List of genes upregulated by LMP1
Type of gene Fold induction
Tumor necrosis factor, alpha-induced protein 3 4.2
Interferon-induced protein with tetratricopeptide
repeats 2
3.8
Egr-1 (Early growth response 1) 3.2
Insulin-like growth factor binding protein 3 2.9
Aldo–keto reductase family 1, member C1 2.8
Major histocompatibility complex, class I, B 2.6
Interferon gamma receptor 1 2.3
Nuclear factor of kappa light polypeptide
gene enhancer in B-cells 2 (p49/p100)
2.32.5. Western blot analysis
Whole cells lysates were prepared in ice-cold RIPA buﬀer [0.5% so-
dium deoxycholate, 1% Nonidet P-40, 150 mM NaCl, 50 mM Tris (pH
7.5), 0.1% SDS, and 1 mM PMSF] and cleared by microcentrifugation
(14000 rpm for 30 min at 4 C). The resulting lysates were assessed for
protein concentration, and 20–30 lg of each protein sample was re-
solved by 12% SDS–polyacrylamide gel electrophoresis (SDS–PAGE),
and electroblotted onto nitrocellulose membranes. After 1 h incuba-
tion in blocking solution (5% non-fat milk), the membranes were ex-
posed to the appropriate primary antibodies overnight at 4 C. The
primary antibodies included those against Egr-1 (Santa Cruz Biotech-
nology, Santa Cruz, CA), LMP1 (Dako, Denmark), p-p65 (Cell
Signaling, Beverly, MA), p65 (Santa Cruz), Bﬂ-1 (Santa Cruz), and
b-actin (Sigma, St. Louis, MO). The blots were then washed and
exposed to HRP-conjugated secondary antibodies for 1 h at room tem-
perature. The results were visualized using an ECL system (Amersham
Pharmacia Biotech, Arlington Heights, IL).Transforming growth factor, beta 1 2.3
Mitogen-activated protein kinase kinase kinase 8 2.2
Interferon, alpha-inducible protein
(clone IFI-6-16)
2.1
Proteasome (prosome, macropain) subunit,
beta type, 10
2.0
TGFB inducible early growth response 2.0
The fold indicates the induction over the control plasmid (pcDNA)-
infected cells as determined by the analysis of human cDNA micro-
array.2.6. siRNA synthesis and transfection
Egr-1-targeting siRNA (5 0-AGA GGC AUA CCA AGA UCC
ATT-30 and its corresponding complementary strand 5 0-UGG AUC
UUG GUA UGC CUC UTT-30) and control siRNA were
obtained from Invitrogen (Carlsbad, CA). MCF7 cells were
plated overnight in 6-well plates and then transfected with the Egr-1
siRNA or control siRNA, using the Lipofectamine 2000 transfec-
tion reagent (Invitrogen), according to the manufacturer’s instruc-
tions.2.7. Cell survival analysis
Cells were incubated in triplicate in a 96-well plate in a ﬁnal volume
of 0.1 ml for 24 h at 37 C, and then 0.025 ml MTT (3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution (5 mg/ml in
PBS) was added to each well. After a 2-h incubation at 37 C, we
added 0.1 ml dye extraction buﬀer (20% SDS, 50% dimethylformam-
ide), continued the incubation for 6 h at 37 C, and then measured
the optical density (OD) at 590 nm, using a 96-well multiscanner auto-
reader with the extraction buﬀer used as a blank. Cell viability was ex-
pressed as a percentage: (OD of the experiment samples/OD of the
control) · 100.
2.8. In situ hybridization and patient data
The tissues used in this study were obtained from 13 patients diag-
nosed with peripheral T-cell lymphoma unspeciﬁed (PTCL-u), accord-
ing to the WHO criteria. EBV RNA was detected by in situ
hybridization, as previously described [21]. Brieﬂy, paraﬃn sections
were pretreated with xylene, treated with proteinases K, and then
hybridized with FITC-conjugated EBV oligonucleotides (Novocastra,
UK) complementary to the nuclear RNA portion of the genes encod-
ing EBER 1 and 2, which are commonly used markers for EBV infec-
tion. EBV negative lymphoid tissues and oligonucleotide-free
hybridization mixtures were used as negative controls. Clinical data
were collected by a retrospective review of medical records.3. Results
3.1. LMP1 induces expression of endogenous Egr-1 in MCF7
and Jurkat cells
To identify genes transcriptionally regulated by LMP1, we
transiently transfected the LMP1-negative MCF7 human
breast cancer cell line with an LMP1-expressing plasmid.
Twenty-four hours later, we compared gene expression proﬁles
between transfected and untransfected cells, using a commer-
cially available cDNA microarray containing 17448 human
genes. Among them, the expression levels of 53 genes were
augmented more than 2-fold (by t-test) in LMP1-expressing
cells versus controls (representative genes are listed in Table
1). Based on its known involvement in cancer signaling, we se-
lected Egr-1 for additional characterization in terms of the ef-
fects of LMP1 on human cancer cells. We ﬁrst used RT-PCR
and Western blot analysis to investigate Egr-1 mRNA and
protein levels in LMP1-negative MCF7 and Jurkat cells and
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Fig. 1. LMP1 enhances the expression of Egr-1 in cancer cell lines. (A)
MCF7 and Jurkat cells were transiently transfected with an expression
vector encoding LMP1, total RNA was extracted, and Egr-1 and
LMP1 mRNA levels were assessed by RT-PCR 24 h post-transfection.
The endogenous mRNA levels of LMP1 and Egr-1 were assessed in
EBV-positive HANK1 and -negative NKL cells by RT-PCR. (B)
MCF7 cells were transfected with LMP1-encoding construct, and the
protein levels of Egr-1 and LMP1 were assessed by Western blotting.
The endogenous protein levels of LMP1 and Egr-1 were assessed in
EBV-positive HANK1 and -negative NKL cells by Western blotting.
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sient expression of LMP1 led to enhancement of Egr-1 mRNA
(Fig. 1A) and protein (Fig. 1B) expression levels. Analysis of
Egr-1 expression in EBV-positive HANK1 cells and EBV-neg-
ative NKL cells showed that the endogenous level of Egr-1 was
higher in HANK1 cells than in NKL cells (Fig. 1).
3.2. Cell survival is enhanced by LMP1 and Egr-1
To determine whether LMP1 enhances drug resistance by
promoting cell survival, we examined the eﬀects of doxorubicin
on cell survival of MCF7 and Jurkat cells transiently express-
ing LMP1 or Egr-1. As shown in Fig. 2, the median inhibitory
concentration (IC50) of doxorubicin was 42 nM in controlpcDNA LMP1 Egr1
0
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Fig. 2. Eﬀects of LMP1 and Egr-1 on cell survival. MCF-7 (A) and Jurka
incubated for 24 h, transiently transfected with the indicated plasmids, and th
MTT assay. IC50 values were calculated from the respective sigmoidal do
obtained from cells transfected with pcDNA (control) versus LMP1-overexp
cells, as indicated.MCF7 cells, whereas that for LMP1-transfected MCF7 cells
was 190 nM (P = 0.0002). Expression of LMP1 also induced
doxorubicin resistance in Jurkat cells, with the IC50 values
increasing from 7.25 ± 2.52 nM to 27 ± 3.07 nM (Fig. 2,
P = 0.0033). Egr-1 expression in MCF7 cells also signiﬁcantly
increased the IC50 for doxorubicin (from 42 nM to over
300 nM, P = 0.0071; Fig. 2). These ﬁndings suggest that
expressions of LMP1 and its target Egr-1 contribute to the
enhancement of drug resistance in cancer cells.
3.3. LMP1-mediated cell survival is diminished by Egr-1 siRNA
Since Egr-1 increased the survival of doxorubicin-challenged
cells, we next examined doxorubicin sensitivity in Egr-1-de-
pleted cells. Targeted siRNA were used to suppress Egr-1
expression in MCF7 cells, as conﬁrmed by Western blots
showing a signiﬁcant reduction in Egr-1 protein levels 72 h
post-transfection (Fig. 3A), but no change in actin levels
(endogenous control). As shown in Fig. 3B, survival analysis
revealed that Egr-1 knockdown caused a dramatic reduction
in LMP1-mediated cell survival in cells exposed to doxorubicin
for three days (IC50 = 14 nM), as compared to control siRNA-
transfected cells (IC50 = 302 nM). Complementing a previous
study showing that Egr-1 expression was induced by doxorubi-
cin treatment [22], our present results indicate that modulation
of Egr-1 may play a critical role in LMP1-induced cell survival.
Interestingly, Egr-1 siRNA did not reduce the survival of
LMP1-negative MCF7 cells (Fig. 3B). Together, these results
show that modulation of Egr-1 may play a critical role in
LMP1-positive cell survival.
3.4. LMP1-induced Egr-1 expression is mediated by NFjB
Since a number of reports have indicated that multiple
LMP1-induced phenotypic changes are associated with
LMP1-mediated activation of NFjB [9,11], we next examined
whether NFjB activity was required for the LMP1-mediated
induction of Egr-1. As shown in Fig. 4A, p65 was induced in
doxorubicin-treated MCF7 cells expressing wild-type LMP1.
Furthermore, treatment with SN50, a compound that prevents
nuclear translocation of the activated NFjB complex [20], de-
creased LMP1-mediated enhancement of Egr-1 expression
(Fig. 4B). We veriﬁed that NF-kB-binding is required forB
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Fig. 3. Egr-1 knockdown diminishes LMP1-induced cell survival. (A) MCF7 cells were transiently transfected with plasmids encoding LMP1 or the
control (pcDNA), incubated for 24 h, and then additionally transfected with siCTL or siEgr-1 for siRNA-mediated knockdown of Egr-1 expression.
Western blot analysis shows that Egr-1 expression was eﬃciently reduced at 72 h after transfection of siEgr-1, whereas actin expression was
unaﬀected. Dose response curves (B) and a summary table (C) detail the eﬀects of LMP1 expression with or without Egr-1 knockdown on the survival
of cell. Cells (1 · 104/well in 96-well plates) treated with indicated doses of doxorubicin for 72 h, followed by MTT assay.
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Fig. 4. LMP1-induced enhancement of Egr-1 expression requires activation of NFjB. (A) Cells were transiently transfected with pcDNA or the
LMP1-encoding vector, treated with doxorubicin (0.5 lM) for the indicated durations, and subject to Western blot. The results revealed that NFjB
phosphorylation in response to doxorubicin was enhanced in LMP1-overexpressing cells. (B) Eﬀect of NFjB inhibitor, SN50. (Left) LMP1-
overexpressing MCF7 cells were treated with NFjB inhibitor (SN50, Upstate Biotechnology, Lake Placid, NY) for 4 h, and Egr-1 expression, LMP1
expression, and NFjB phosphorylation were analyzed. The results revealed that inhibition of NFjB decreases LMP1-induced enhancement of Egr-1
expression. (Right) LMP1-expressing cells were cultured with doxorubicin (0.5 lM) in the presence (+) or absence () of SN-50 (10 lM), and were
then ﬁxed and stained with an anti-NFjB p65 antibody or DAPI to detect nuclear translocation of NFjB. The results revealed that SN50 blocks
nuclear translocation of NFjB. (C) Cells were transiently transfected with pcDNA, or plasmids expressing LMP1 or an NFjB binding-defective
LMP1D NFjB mutant. Western blot shows that NFjB is required for LMP1-induced enhancement of Egr-1 expression. (D) MCF7 cells were
transiently transfected with control vector or constructs encoding Egr-1, constitutively active Egr-1 (Egr1*) or LMP1 followed by incubation for 48 h.
Western blot analysis for the expression of LMP1, Egr-1 and Bﬂ-1 revealed that Egr-1 induces Bﬂ-1. (E) LMP1-expressing MCF7 cells were
transfected with siEgr-1 and incubated for 24, 48, and 72 h. Western blot analysis for expression of Egr-1 and Bﬂ-1 revealed that Egr-1 knockdown
reduces LMP1-induced enhancement of Bﬂ-1 expression.
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these experiments with LMP1 mutants lacking the ability toactivate NF-kB (Fig. 4C). The involvement of NFjB
prompted us to investigate whether Egr-1 enhancement af-
Table 2
Relationship between EBV positivity, Egr-1 expression and primary
refractory
EBV (+) EBV () P-valuea
Egr-1 (+) 2/3 0/10 0.038
Primary refractory 3/3 1/9 0.012
aThe associations between EBV status and Egr-1 expression or primary
refractory were assessed using Fisher’s exact tests.
J.H. Kim et al. / FEBS Letters 581 (2007) 623–628 627fected expression of the anti-apoptotic protein, Bﬂ-1. As
shown in Fig. 4D and E, separate transfections with vectors
encoding Egr-1, a constitutively active Egr-1 mutant or
LMP1 all induced expression of Bﬂ-1, and this expression
was reduced by Egr-1 knockdown. As LMP1 and Egr-1 can
regulate expression of many genes in a cell type-speciﬁc man-
ner, Bﬂ-1 may be associated with LMP1/Egr-1-mediated sur-
vival of doxorubicin-challenged MCF7 cells.
3.5. EBV infection is associated with Egr-1 expression and drug
resistance
To examine the above interactions in vivo, we examined the
expression level ofEBVEBERandEgr-1 in 13 tumor tissue sam-
ples from PTCL-u patients. Among the 13 samples, three were
EBER-positive and 10 were EBER-negative. Egr-1 expression
was increased in 2 of 3 EBER-positive PTCL-u specimens, albeit
in a limited dataset (P = 0.038, Table 2). Moreover, primary
chemotherapy resistance was observed in all three EBER-posi-
tive patients, but only one primary refractory was observed in
9 treated EBER-negative patients (P = 0.012, Table 2).4. Discussion
LMP-1 is an integral membrane protein consisting of a short
N-terminal cytoplasmic domain, six membrane-spanning do-
mains, and a long cytoplasmic C-terminus containing several
transcription activating regions that may be recognized by
members of the tumor necrosis factor (TNF) receptor-associ-
ated family [23]. Expression of LMP-1 promotes cell survival
by activating factors such as NFjB, c-JNK and AP-1
[11,24], and by regulating STAT1 via NFjB [25]. LMP1 is be-
lieved to be involved in cell survival of EBV-infected cancer
cells, but the potential mechanisms governing LMP1-mediated
modulation of gene transcription during survival signaling are
not fully understood. Here, we sought to improve our knowl-
edge of this signaling through the identiﬁcation of downstream
cellular targets that are directly or indirectly regulated by
LMP1 in human cells.
Microarray analysis of genes showing diﬀerential expression
in MCF7 and Jurkat cells in the presence and absence of
LMP1 expression (Table 1) revealed enhanced expression of
the transcription factor, Egr-1, in LMP1-expressing MCF7
and Jurkat cells. RT-PCR and Western blot analyses con-
ﬁrmed this diﬀerential expression, suggesting that LMP1
induces expression of Egr-1. Previous papers reported
LMP1-induced expression of cellular genes such as bcl-2 or
IL-6, a ﬁnding not shown in our result. Although the precise
mechanism of LMP1 action is unknown, LMP1 has been
reported to regulate many other proteins [23]. Diﬀerential
function of LMP1 may be determined by the interaction with
these proteins in a cell type-speciﬁc manner.Previous studies have shown that growth factors induce Egr-
1 expression, leading to transduction of proliferation signals.
Interestingly, induction of Egr-1 in prostate tumor was shown
to stimulate tumor cell growth [26], but Egr-1 expression is of-
ten absent or reduced in breast and lung tumor cells [27]. In
certain tumor cells, forced expression of Egr-1 has anti-apop-
totic eﬀects [14,28], but other studies have shown that Egr-1
is required for programmed cell death or apoptosis in
both normal and tumor cells [27,29]. These contradictory
results may be explained by the overlapping binding site of
Egr-1 and Sp1. Many growth-promoting genes have a GC-rich
binding region for activation by the Sp1 zinc-ﬁnger protein.
Egr-1 has a similar binding site, and if the two sites occur in
the same region, Egr-1 can displace Sp1 and inhibit its activity
[30,31].
Although studies have shown that Egr-1 can increase cell
survival by allowing cell clonogenicity to proceed at higher lev-
els than in the absence of Egr-1 [28], the precise role of Egr-1 in
this context is not yet clear. In the present study, we found that
LMP1-induced drug resistance was abrogated by siRNA
knockdown of Egr-1, indicating that Egr-1 could be a key tar-
get for LMP1-induced tumor cell survival. Our microarray
analysis additionally revealed LMP1-induced enhancement of
various NFjB-related genes, including TNFAIP3 and
NFKB2, and further experiments revealed that the NFjB
inhibitor, SN50, reduced the enhanced expression of Egr-1
seen in LMP1-expressing cells. These results seem to collec-
tively suggest that LMP1 may activate Egr-1 via NFjB.
In sum, we herein show for the ﬁrst time that Egr-1 is a
downstream cellular target of LMP1 via NFjB in malignant
breast and T cells. These ﬁndings suggest that Egr-1 may be
a candidate for new therapeutic interventions aimed at EBV-
associated tumors.Acknowledgement: This work was supported by the Samsung Biomed-
ical Research Institute (Grant # SBRI C-A-53081).References
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